About BioCision


BioCision is a life science research and development company that develops products and solutions for process standardization throughout the healthcare industry through the application of advanced thermal regulation principles and technologies. The intuitive design and interconnectivity of BioCision products enables researchers, clinicians and manufacturers to protect the integrity of temperature-sensitive therapeutics, biological samples, and biomaterials.  By comprehensively addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.




Rolf Ehrhardt, MD, PhD

President and Chief Executive Officer

Dr. Rolf Ehrhardt co-founded BioCision in 2007, after more than 25 years of experience in leadership and innovation in medical research and product development. Prior to growing BioCision into the leading provider of temperature-sensitive sample and drug handling solutions, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery and immuno-therapeutics development at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.


Ron DiNocco

Chief Financial Officer

Mr. DiNocco joined BioCision in 2008 managing corporate finance development with responsibility for long term capital strategy and investor relations. From 2000-2008 he served multiple leadership roles at Akiva Corporation, including CFO and CEO, while achieving global expansion through new customer and government relationships. During this time, Mr. DiNocco was able to successfully close an institutional Series A round and negotiated the acquisition of a division of O'Reilly and Associates. He holds a bachelor's degree from Babson College and has also completed International Business studies at the University of Monash in Australia. Mr. DiNocco serves on the board of Tech Coast Angels and is an active supporter of early stage companies.


Michelle Nemits

Chief Commercial Officer

Ms. Nemits joined BioCision in 2008, with almost 20 years of experience in sales of laboratory products and services. Previously, she was Director of Business Development at VWR International LLC, a $4 billion global laboratory supply distributor, where she forged partnerships with and customized services for global biopharmaceutical customers with complex supply chain requirements. During her 11-year tenure at VWR, Ms. Nemits held various sales and management positions in the global accounts division. Prior to joining VWR, she held sales and marketing positions with Wheaton Science Products of Millville, New Jersey, and Ishihara Sangyo Kaisha, a Japanese chemical manufacturer with U.S. sales operations based in the San Francisco Bay Area.


Eric J. Kunkel, PhD

Senior Vice President, Research and Development

Dr. Kunkel has over 12 years of experience in biotechnology including executive positions in R&D, entrepreneurship and start-ups, and consulting for technology and diagnostics companies. As an entrepreneur, he co-founded Ascellna Life Science Group, a business development and commercialization company for small companies with innovative technologies and Extend Biopharma, a start-up company developing a chemoenzymatic technology for creating next generation biologics. As VP, Assay Development and Screening at Catalyst Biosciences, Inc., Dr. Kunkel led the optimization of the company’s Alterase technology platform, which successfully generated multiple development candidates. Dr. Kunkel has published thirty-seven articles in peer-reviewed journals and has contributed to multiple patents and patent applications. He holds a B.Sc in Chemical Engineering from the University of Notre Dame, M.S. and Ph.D. degrees in Biomedical Engineering from the University of Virginia, and was a postdoctoral fellow at Stanford University.



Samuel Kent

Senior Vice President, Global Sales and Business Development

Mr. Kent joined BioCision in early 2013, with over 13 years of experience in sales of a diverse portfolio of laboratory products and services. Prior to joining BioCision, Mr. Kent served in multiple senior roles at Thermo Fisher Scientific and Parker Hannifin including Commercial Manager North America and Global Business Development Manager. In these positions, he was instrumental in expanding corporate presence and commercial success in the clinical chemistry, academic research, pharmaceutical, food and beverage safety and the analytical environmental markets. Mr. Kent graduated with his MBA from Colorado State University and his B.Sc from Northern Michigan University.



Chris Krueger

Corporate Development

Mr. Krueger supports BioCision with Corporate Development strategy. Previously, he served as a senior executive in both public and private life science companies, including Ardea Biosciences, X-Ceptor Therapeutics and Aurora Biosciences, with operational responsibility and leadership for multiple functional areas, including legal affairs, business development and corporate finance. In these roles, he was responsible for executing and managing a broad range of complex commercial transactions, including strategic alliances, licensing, mergers and acquisitions and equity and debt financings. Earlier in his career, Mr. Krueger was a corporate lawyer at Cooley LLP. Mr. Krueger holds a J.D. and an M.B.A. in Finance from the University of Southern California and a B.A. in Economics from the University of California at San Diego.



Hugh Douglas

Senior Vice President, Strategic Alliances

Mr. Douglas joined BioCision in 2010, with over 35 years in Life Science Operations. Prior to BioCision, Mr. Douglas most recently led Bridge4Bio, LLC, a global business consulting group. Previously, he was managing director and president of Hoefer, Inc., a part of Harvard Bioscience. Mr. Douglas was also vice president of the West Coast operations for Amersham Biosciences, now a part of GE Healthcare. He has been involved in start-ups, acquisitions and spin-outs and has broad experience in managing companies for growth and success. Mr. Douglas holds a B.A. from the University of California, Berkeley and earned his MBA from Golden Gate University.


Brian Schryver

Vice President, Product Development

Mr. Schryver co-founded BioCision in 2007, after a 25-year career in molecular biological research and development. He has extensive experience developing instruments and tooling for the life science field. Prior to co-founding BioCision, Mr. Schryver was a scientist at CFD Therapeutics Inc. and worked in topical formulation and assay development at Corgentech, now Anesiva. Mr. Schryver also was involved in preclinical development and biomarker research at SUGEN, and discovery research at Syntex.



Mark Allen

Vice President, Operations

Mr. Allen joined BioCision in 2015, with over 25 years of experience in operations and supply chain management within the medical device and diagnostics industries. Previously, he was a Principal Consultant with the Securieon Group, a global management and consulting firm. Prior to that, he was Vice President of Operations and co-founder of Aplegen, Inc., a global diagnostic imaging company. He also served as Vice President of Global Operations for Alpha Innotech Corporation, a leading proteomic and genomic diagnostic tools provider. He holds a B.Sc. in Zoology from North Carolina State University.



Katharina Hohenfellner, MD, PhD

Chief Medical Affairs Officer

Katharina Hohenfellner, MD, PhD is the Chief Medical Officer at BioCision. In her role she is responsible for facilitating the integration of BioCison's standardization and automation products into GMP environments and clinical programs. Prof. Hohenfellner oversees the development of new clinical applications; and develops regional educational and research opportunities in partnership with key medical institutions, agencies and industry leaders. Dr. Hohenfellner is Board Certified in Pediatrics at the Children’s Hospital in Johannes Gutenberg-University, Germany. She has a Ph.D. and an M.D. from the University of Mainz. For more than 10 years, Dr. Hohenfeller served as an Associate Professor in the Department of Pediatrics at the University of Mainz and Salzburg. She is a Board Member of the Society of Pediatric Nephrologists.


Maria Thompson, PhD

Scientific Affairs

Dr. Thompson joined BioCision in early 2010, with over 15 years of experience in pharmaceutical and diagnostics research and development. She has held a variety of roles including Head of Genome Wide Screening for Type 2 diabetes, Six Sigma Black Belt, Principal Consultant, and VP of Scientific Affairs, as well as running a private consulting company providing scientific and technical advisory services to clients across the life science industry. Dr. Thompson holds a B.Sc in Genetics and a Ph.D. in Molecular and Cellular Biochemistry from the Royal London School of Medicine, UK.



Lori Kunkel, MD

Principal at D2D, LLC

Advisory Board Chair

Dr. Kunkel brings extensive experience in developing and commercializing oncologic and immunologic therapies, with over 20 years of executive responsibilities in industry including clinical, regulatory, medical affairs and licensing. As chief medical officer at Pharmacyclics, she was instrumental in achieving breakthrough designation for the company’s lead product, ibrutinib. Previously, Dr. Kunkel spent ten years in academic and clinical research and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles.

Lee Buckler, JD

Founder and Managing Director of the Cell Therapy Group

Mr. Buckler is focused on the cell therapy and regenerative medicine industries, consulting on business development strategies, competitive intelligence, market research and analysis, deal-making, marketing and communications, and sales-lead generation. He founded Cell Therapy News and Cell Therapy Blog, and serves on the editorial board of the journals BioProcess International and Regenerative Medicine. Before transitioning to biotech, Mr. Buckler earned a law degree from University of British Columbia and was a practicing commercial attorney.

Scott Burger, MD

Principal at Advanced Cell & Gene Therapy

As principal at Advanced Cell & Gene Therapy, Dr. Burger consults on the development and commercialization of cell therapy, gene therapy, and tissue-engineered products, providing expert assistance in due diligence and strategic partnering, GMP/GTP manufacturing, process development, characterization and comparability, and regulatory affairs. Previously, Dr. Burger spent eight years directing the University of Minnesota Cell Therapy Clinical Laboratory, a GMP laboratory that manufactures cell therapy and gene therapy products for clinical trials and transplantation, and served as VP of R&D at Merix Bioscience, a dendritic cell therapy company.

Jon Rowley, PhD

Chief Executive and Technology Officer of RoosterBio, Inc.

Dr. Rowley has made it his personal goal to make significant contributions to the commercial translation of living cellular technologies. He holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 30 peer reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Dr. Rowley most recently spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy CMO business.

Anthony Davies, PhD

President of Dark Horse Consulting

Anthony Davies, PhD has 20 years experience in the cell and gene therapy field. He is currently the President of Dark Horse Consulting where he focuses on CMC and product development issues in cell and gene therapy. Previously Dr Davies held the position of Chief Technology Officer at Capricor Therapeutics, and led a large, randomized, placebo-controlled clinical trial for an allogeneic cardiac stem cell product. Prior to Capricor, Dr Davies served as VP, Product Development at Geron Corporation and was responsible for all cell therapies’ process and analytical science and manufacturing, including both autologous and allogeneic products. He was schooled in the UK, obtaining a Masters Degree in Natural Sciences from the University of Cambridge and a PhD in Biochemical Engineering.